Inzucchi, Silvio E.

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 7,140

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 3,655

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 3,207

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 3,066

Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 2,884

American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control

Moghissi, E. S., Korytkowski, M. T., DiNardo, M., Einhorn, D., Hellman, R., Hirsch, I. B., Inzucchi, S. E., Ismail-Beigi, F., Kirkman, M. S., & Umpierrez, G. E. (2009) · Diabetes Care

Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Management and Research

Cited by 1,444

Sotagliflozin in patients with diabetes and chronic kidney disease

Bhatt, D. L., Szarek, M., Pitt, B., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Inzucchi, S. E., Kosiborod, M. N., et al. (2021) · New England Journal of Medicine

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,205

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine

Acute Ischemic Stroke ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 1,124

Mechanism by which metformin reduces glucose production in type 2 diabetes.

Hundal, R. S., Krssak, M., Dufour, S., Laurent, D., Lebon, V, Chandramouli, V, Inzucchi, S. E., Schumann, W. C., Petersen, K. F., Landau, B. R., et al. (2000) · Diabetes

Metabolism, Diabetes, and CancerDiabetes Treatment and Management

Cited by 1,052

Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials

Baigent, C., Emberson, J., Haynes, R., Herrington, W. G., Judge, P., Landray, M. J., Mayne, K. J., Ng, S. Y. A., Preiss, D., Roddick, A. J., et al. (2022) · The Lancet

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 1,020

How do we define cure of diabetes?

Buse, J. B., Caprio, S., Cefalu, W. T., Ceriello, A., Del Prato, S., Inzucchi, S. E., McLaughlin, S., Phillips, G. L., Robertson, R. P., Rubino, F., et al. (2009) · Diabetes Care

Diabetes Management and ResearchDiabetes and associated disorders

Cited by 1,003

SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials

Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · The Lancet

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 996

Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME ® trial

Fitchett, D., Zinman, B., Wanner, C., Lachin, J. M., Hantel, S., Salsali, A., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Inzucchi, S. E. (2016) · European Heart Journal

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 907

Cardiac Outcomes After Screening for Asymptomatic Coronary Artery Disease in Patients With Type 2 Diabetes: The DIAD Study: A Randomized Controlled Trial

Young, L. H., Wackers, F. J. T., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., et al. (2009) · JAMA

Cardiac Imaging and DiagnosticsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 809

Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 794

Detection of Silent Myocardial Ischemia in Asymptomatic Diabetic Subjects

Wackers, F. J. T., Young, L. H., Inzucchi, S. E., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Wittlin, S. D., Heller, G. V., Filipchuk, N., et al. (2004) · Diabetes Care

Cardiac Imaging and DiagnosticsCardiovascular Function and Risk Factors

Cited by 791

How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG OUTCOME Trial

Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 740

Impaired Glucose Transport as a Cause of Decreased Insulin-Stimulated Muscle Glycogen Synthesis in Type 2 Diabetes

Cline, G. W., Petersen, K. F., Krssak, M., Shen, J., Hundal, R. S., Trajanoski, Z., Inzucchi, S., Dresner, A., Rothman, D. L., & Shulman, G. I. (1999) · New England Journal of Medicine

Metabolism, Diabetes, and CancerDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 675

Admission Glucose and Mortality in Elderly Patients Hospitalized With Acute Myocardial Infarction: Implications for Patients With and Without Recognized Diabetes

Kosiborod, M., Rathore, S. S., Inzucchi, S. E., Masoudi, F. A., Wang, Y., Havranek, E. P., & Krumholz, H. M. (2005) · Circulation

Hyperglycemia and glycemic control in critically ill and hospitalized patientsAcute Myocardial Infarction Research

Cited by 666

The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes

Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes

Peroxisome Proliferator-Activated ReceptorsAdipose Tissue and Metabolism

Cited by 647

Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review

Inzucchi, S. E., Lipska, K. J., Mayo, H., Bailey, C. J., & McGuire, D. K. (2014) · JAMA

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 601

Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes

Hundal, R. S., Petersen, K. F., Mayerson, A. B., Randhawa, P. S., Inzucchi, S., Shoelson, S. E., & Shulman, G. I. (2002) · Journal of Clinical Investigation

Diabetes Treatment and ManagementAdipokines, Inflammation, and Metabolic Diseases

Cited by 557

Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes

Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlávek, J., Böhm, M., Chiang, C.-E., Chopra, V. K., de Boer, R. A., et al. (2020) · JAMA

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 531

Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease

Wanner, C., Lachin, J. M., Inzucchi, S. E., Fitchett, D., Mattheus, M., George, J., Woerle, H. J., Broedl, U. C., von Eynatten, M., & Zinman, B. (2018) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 469